Honasa buys 58% of Fluence Pharma at ₹135 cr EV, enters ₹16,000-cr nutraceuticals category
Mamaearth-parent Honasa Consumer is acquiring 58% of Gurugram-based Fluence Pharma at a ₹135 crore enterprise value, with the remaining 42% over 5-7 years. The deal launches new subsidiary Honasa Health, marking entry into India's ₹16,000-crore nutraceuticals market growing at 11%.
Honasa Consumer acquires 58% of nutraceuticals firm Fluence Pharma at ₹135 crore EV, with remaining 42% over 5-7 years, marking Mamaearth-parent's entry into India's ₹16,000-crore nutraceuticals category via new subsidiary Honasa Health.